| 前收市價 | 100.22 |
| 開市 | 100.90 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 100.42 - 101.68 |
| 52 週波幅 | 80.60 - 106.14 |
| 成交量 | |
| 平均成交量 | 1,448,318 |
| 市值 | 126.872十億 |
| Beta 值 (5 年，每月) | 0.42 |
| 市盈率 (最近 12 個月) | 30.13 |
| 每股盈利 (最近 12 個月) | 3.36 |
| 業績公佈日 | 2024年10月25日 |
| 遠期股息及收益率 | 3.76 (3.75%) |
| 除息日 | 2024年5月13日 |
| 1 年預測目標價 | 106.90 |
BloombergSanofi Is Said to Ask Bidders to Revise Consumer Health Offers
(Bloomberg) -- Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. Most Read from BloombergA 7,000-Year-Old City Emerges as a Haven from Dubai’s Sky-High RentsGang Violence Is Moving to the Amazon’s Fast-Growing CitiesA Housing Crisis Brews in Rwanda’s Capital CityNew Rowhouses in London That Offer a Bridge to the 19th CenturyClimate Migrants Stand to Overwhel
ZacksSanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Investor's Business DailyRegeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
